Filing Flows › Heron Therapeutics (HRTX) › Recalls, complaints & regulation
Heron Therapeutics (HRTX): recalls and clinical trials
Heron Therapeutics (HRTX) beyond its filings: 0 recalls in the last 12 months (1 in five years, 0 Class I); 2 active clinical trials.
Latest recalls
- 2022-08-24 · FDA drug · Zynrelef (bupivacaine and meloxicam), 400 mg bupivacaine and 12 mg meloxicam single dose application, packaged in a kit, Rx only, Manufactured for Heron Therape
Heron Therapeutics' latest quarter
Heron Therapeutics, Q2 2026: revenue $37.7M (+1% year over year), operating margin -5.4%, net loss $5.5M, operating cash flow −$2.2M. The chart follows the revenue to costs, profit and cash.
Questions
Has Heron Therapeutics had any recalls?
1 recall on file over five years from the FDA, CPSC and NHTSA; 0 in the last 12 months.
How many clinical trials does Heron Therapeutics have?
2 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.